Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406726 · ClinicalTrials.gov registry record · NA
Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis
A NA study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT05406726 is a NA study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 13 participants.
The verdict
NCT05406726, a NA study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purposes of this 1-year proof of feasibility and acceptability pilot study are twofold. First to determine if participants with knee osteoarthritis (KOA) will comply with taking palmitoylethanolamide (PEA) dietary supplement for 6 weeks and adhere to taking it as directed. Second is to gain preliminary data to elucidate mechanisms (protein signatures, inflammatory markers and neurobiological signaling pathways) by which PEA, a lipid-based endocannabinoid, works to alter pain sensitivity in adults with KOA. In the simplest terms possible, we need to provide evidence that PEA changes the protein signature in order to provide evidence to establish mechanism.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT palmitoylethanolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-03-22 |
| Est. Completion | 2024-01-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05406726
The ClinicalTrials.gov registry entry for NCT05406726 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05406726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05406726 about?
NCT05406726 is a clinical study titled "Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis". The purposes of this 1-year proof of feasibility and acceptability pilot study are twofold. First to determine if participants with knee osteoarthritis (KOA) will comply with taking palmitoylethanolamide (PEA) dietary supplement for 6 weeks and adhere to taking it as directed. Second is to gain prel...
What is the current status of trial NCT05406726?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2023-03-22. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT05406726?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), palmitoylethanolamide (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05406726?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.